SOPHiA GENETICS presents 25% revenue growth in Q3 2026
SOPH•SOPHiA GENETICS reported Q3 2026 revenue of $24.27 million, up 25% year over year, and narrowed its adjusted EBITDA loss to $6.07 million. Analysis volume rose 19% to a record 118,000, while the company announced a multiyear AstraZeneca agreement.
1. Quarterly results
SOPHiA GENETICS reported third-quarter 2026 revenue of $24.27 million, up 25% year over year. Its adjusted EBITDA loss narrowed to $6.07 million from $8.84 million a year earlier. Analysis volume increased 19% to a record 118,000, and net dollar retention reached 118%.
2. Growth and agreement
US revenue grew 41%, while liquid biopsy revenue more than doubled. A multiyear AstraZeneca agreement covers two companion diagnostic programs targeting solid tumors and blood cancer.
